Brain abnormalities in schizophrenia

Schizophrenia, Second Edition

Volumn , Issue , 2009, Pages 87-104

  Bogerts, Bernhard ^a   Steiner, Johann ^a   Bernstein, Hans Gert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85120403683     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420080063-11     Document Type: Chapter

References (175)

1. Bogerts B, Liebermann J. Neuropathology in the study of psychiatric disease. In: Costa e Silva A, Nadelson CC, eds. In International Review of Psychiatry. Washington DC: American Psychiatric Press, 1993: 515–55.
2. Huber G. Chronische Schizophrenie, Synopsis klinischer und neuroradiologischer Untersuchungen. Heidelberg: Hütig-Verlag, 1961.
3. Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry 1973; 29: 177–89.
4. Torrey EF, Peterson MR. Schizophrenia and the limbic system. Lancet 1974; 2: 942–6.
5. Bogerts B. Zur Neuropathologie der Schizophrenien. Fortschr Neurol Psychiatr 1984; 52: 428–37.
6. Bogerts B. Schizophrenien als Erkrankungen des limbischen Systems. In: Huber G, ed. Basisstadien endogener Psychosen und das Borderline-Problem. Stuttgart: Schattauer, 1985: 163–79.
7. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985; 42: 784–91.
8. Woodruff PW, Wright IC, Shuriquie N et al. Structural brain abnormalities in male schizophrenics reflect fronto-temporal dissociation. Psychol Med 1997; 27: 1257–66.
9. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl) 2004; 174: 151–62.
10. Chance SA, Esiri MM, Crow TJ. Amygdala volume in schizophrenia: post-mortem study and review of magnetic resonance imaging findings. Br J Psychiatry 2002; 180: 331–8.
11. Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia, and neurotransmitter-specific projection systems. Schizophr Bull 1997; 23: 403–21.
12. Wang L, Hosakere M, Trein JC et al. Abnormalities of cingulate gyrus neuroanatomy in schizophrenia. Schizophr Res 2007; 93: 66–78.
13. Krimer LS, Herman MM, Saunders RC et al. A qualitative and quantitative analysis of the entorhinal cortex in schizophrenia. Cereb Cortex 1997; 7: 732–9.
14. Kalus P, Slotboom J, Gallinat J et al. New evidence for involvement of the entorhinal region in schizophrenia: a combined MRI volumetric and DTI study. Neuroimage 2005; 24: 1122–9.
15. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998; 172: 110–20.
16. Wright IC, Rabe-Hesketh S, Woodruff PW et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000; 157: 16–25.
17. Kreczmanski P, Heinsen H, Mantua V et al. Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. Brain 2007; 130: 678–92.
18. Bernstein HG, Krause S, Krell D et al. Strongly reduced number of parvalbumin– immunoreactive projection neurons in the mammillary bodies in schizophrenia: further evidence for limbic neuropathology. Ann N Y Acad Sci 2007; 1096: 120–7.
19. Brisch R, Bernstein HG, Krell D et al. Volumetric analysis of septal region in schizophrenia and affective disorder. Eur Arch Psychiatry Clin Neurosci 2007; 257: 140–8.
20. Ranft K, Krell D, Danos P et al. Reduced volumes of the habenular complex in depression. World J Biol Psychiatry 2002; 3: 27.
21. Dwork AJ. Postmortem studies of the hippocampal formation in schizophrenia. Schizophr Bull 1997; 23: 385–402.
22. Reif A, Fritzen S, Finger M et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514–22.
23. Burns J, Job D, Bastin ME et al. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry 2003; 182: 439–43.
24. Talamini LM, Meeter M, Elvevag B et al. Reduced parahippocampal connectivity produces schizophrenia-like memory deficits in simulated neural circuits with reduced parahippocampal connectivity. Arch Gen Psychiatry 2005; 62: 485–93.
25. Sawada K, Barr AM, Nakamura M et al. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry 2005; 62: 263–72.
26. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 2006; 60: 132–40.
27. Heckers S, Stone D, Walsh J et al. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002; 59: 521–9
28. Woodruff-Pak DS, Gould TJ. Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer′s disease and schizophrenia. Behav Cogn Neurosci Rev 2002; 1: 5–20.
29. Bernstein HG, Krell D, Emrich HM et al. Fewer beta-endorphin expressing arcuate nucleus neurons and reduced beta-endorphinergic innervation of paraventricular neurons in schizophrenics and patients with depression. Cell Mol Biol (Noisy-le-grand) 2002; 48 Online Pub: OL259–65.
30. Beveridge NJ, Tooney PA, Carroll AP et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17(8): 1156–68.
31. Bernstein HG, Braunewell KH, Spilker C et al. Hippocampal expression of the calcium sensor protein visinin-like protein-1 in schizophrenia. Neuroreport 2002; 13: 393–6.
32. Bogerts B. The temporolimbic system theory of positive schizophrenic symptoms. Schizophr Bull 1997; 23: 423–35.
33. Gruber O, Falkai P, Schneider-Axmann T et al. Neuregulin-1 haplotype HAP(ICE) is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. J Psychiatr Res 2008; 43(1): 1–6.
34. Heckers S, Heinsen H, Heinsen Y et al. Cortex, white matter, and basal ganglia in schizophrenia: a volumetric postmortem study. Biol Psychiatry 1991; 29: 556–66.
35. Berretta S, Pantazopoulos H, Lange N. Neuron numbers and volume of the amygdala in subjects diagnosed with bipolar disorder or schizophrenia. Biol Psychiatry 2007; 62: 884–93.
36. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986; 65: 303–26.
37. Arnold SE, Hyman BT, Van Hoesen GW et al. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991; 48: 625–32.
38. Falkai P, Schneider-Axmann T, Honer WG. Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. Biol Psychiatry 2000; 47: 937–43.
39. Kovalenko S, Bergmann A, Schneider-Axmann T et al. Regio entorhinalis in schizophrenia: more evidence for migrational disturbances and suggestions for a new biological hypothesis. Pharmacopsychiatry 2003; 36 Suppl 3: S158–61.
40. Heinsen H, Gossmann E, Rub U et al. Variability in the human entorhinal region may confound neuropsychiatric diagnoses. Acta Anat (Basel) 1996; 157: 226–37.
41. Bernstein HG, Krell D, Baumann B et al. Morphometric studies of the entorhinal cortex in neuropsychiatric patients and controls: clusters of heterotopically displaced lamina II neurons are not indicative of schizophrenia. Schizophr Res 1998; 33: 125–32.
42. Braitenberg V. Ricerche istopatologiche sulla corteccia frontale di schizofrenici. Proceedings of the First International Congress of Neuropathology. Turin: Rosenberg & Sellier, 1952: 621–6.
43. Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987; 44: 608–16.
44. Bouras C, Kovari E, Hof PR et al. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol 2001; 102: 373–9.
45. Benes FM, Vincent SL, Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry 2001; 50: 395–406.
46. Cotter D, Landau S, Beasley C et al. The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002; 51: 377–86.
47. Todtenkopf MS, Vincent SL, Benes FM. A cross-study meta-analysis and three-dimensional comparison of cell counting in the anterior cingulate cortex of schizophrenic and bipolar brain. Schizophr Res 2005; 73: 79–89.
48. Woo TU, Walsh JP, Benes FM. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004; 61: 649–57.
49. Chana G, Landau S, Beasley C et al. Two-dimensional assessment of cytoarchitecture in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia: evidence for decreased neuronal somal size and increased neuronal density. Biol Psychiatry 2003; 53: 1086–98.
50. Gittins R, Harrison PJ. Neuronal density, size and shape in the human anterior cingulate cortex: a comparison of Nissl and NeuN staining. Brain Res Bull 2004; 63: 155–60.
51. Kalus P, Senitz D, Beckmann H. Altered distribution of parvalbumin-immunoreactive local circuit neurons in the anterior cingulate cortex of schizophrenic patients. Psychiatry Res 1997; 75: 49–59.
52. Aganova EA, Uranova NA. Morphometric analysis of synaptic contacts in the anterior limbic cortex in the endogenous psychoses. Neurosci Behav Physiol 1992; 22: 59–65.
53. Stark AK, Uylings HB, Sanz-Arigita E et al. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 2004; 161: 882–8.
54. Steiner J, Bernstein HG, Bielau H et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. J Psychiatr Res 2007; 42(10): 868–76.
55. McCullumsmith RE, Gupta D, Beneyto M et al. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 2007; 90: 15–27.
56. Law AJ, Harrison PJ. The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res 2003; 37: 487–99.
57. Wheeler DG, Dixon G, Harper CG. No differences in calcium-binding protein immunoreactivity in the posterior cingulate and visual cortex: schizophrenia and controls. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 630–9.
58. Schlaepfer TE, Harris GJ, Tien AY et al. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 1994; 151: 842–8.
59. Gur RE, Cowell PE, Latshaw A et al. Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch Gen Psychiatry 2000; 57: 761–68.
60. Galderisi S, Quarantelli M, Volpe U et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 2008; 34: 393–401.
61. Reynolds GP, Beasley CL, Zhang ZJ. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J Neural Transm 2002; 109: 881–9.
62. Cotter D, Mackay D, Chana G et al. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002; 12: 386–94.
63. Akbarian S, Kim JJ, Potkin SG et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258–66.
64. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu Rev Neurosci 2002; 25: 409–32.
65. Hashimoto T, Bazmi HH, Mirnics K et al. Conserved Regional Patterns of GABA-Related Transcript Expression in the Neocortex of Subjects With Schizophrenia. Am J Psychiatry 2008; 165(4): 479–89
66. Tooney PA, Chahl LA. Neurons expressing calcium-binding proteins in the prefrontal cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 273–8.
67. Bernstein HG, Sahin J, Smalla KH et al. A reduced number of cortical neurons show increased Caldendrin protein levels in chronic schizophrenia. Schizophr Res 2007; 96: 246–56.
68. Selemon LD, Mrzljak J, Kleinman JE et al. Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca′s area 44 and area 9. Arch Gen Psychiatry 2003; 60: 69–77.
69. Selemon LD, Rajkowska G, Goldman-Rakic PS. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol 1998; 392: 402–12.
70. Cullen TJ, Walker MA, Eastwood SL et al. Anomalies of asymmetry of pyramidal cell density and structure in dorsolateral prefrontal cortex in schizophrenia. Br J Psychiatry 2006; 188: 26–31.
71. Hashimoto R, Straub RE, Weickert CS et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004; 9: 299–307.
72. Chong VZ, Thompson M, Beltaifa S et al. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophr Res 2008; 100: 270–80.
73. Bertram I, Bernstein HG, Lendeckel U et al. Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression. Ann N Y Acad Sci 2007; 1096: 147–56.
74. Hahn CG, Wang HY, Cho DS et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 824–8.
75. Weis S, Llenos IC. GFAP-immunopositive astrocytes in schizophrenia. Schizophr Res 2004; 67: 293–95.
76. Kirkpatrick B, Conley RC, Kakoyannis A et al. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study. Synapse 1999; 34, 95–102.
77. Kirkpatrick B, Messias NC, Conley RR et al. Interstitial cells of the white matter in the dorsolateral prefrontal cortex in deficit and nondeficit schizophrenia. J Nerv Ment Dis 2003; 191: 563–7.
78. Eastwood SL, Harrison PJ. Interstitial white matter neuron density in the dorsolateral prefrontal cortex and parahippocampal gyrus in schizophrenia. Schizophr Res 2005; 79: 181–8
79. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94: 273–80.
80. Segal D, Koschnick JR, Slegers LH et al. Oligodendrocyte pathophysiology: a new view of schizophrenia. Int J Neuropsychopharmacol 2007; 10: 503–11.
81. Harms MP, Wang L, Mamah D et al. Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. J Neurosci 2007; 27: 13835–42.
82. Lesch A, Bogerts B. The diencephalon in schizophrenia: evidence for reduced thickness of the periventricular grey matter. Eur Arch Psychiatry Neurol Sci 1984; 234: 212–9.
83. Jones EG. Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997; 23: 483–501.
84. Pakkenberg B. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophr Res 1992; 7: 95–100.
85. Pakkenberg B, Gundersen HJ. New stereological method for obtaining unbiased and efficient estimates of total nerve cell number in human brain areas. Exemplified by the mediodorsal thalamic nucleus in schizophrenics. Apmis 1989; 97: 677–81.
86. Popken GJ, Bunney WE Jr, Potkin SG et al. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc Natl Acad Sci USA 2000; 97: 9276–80.
87. Young KA, Manaye KF, Liang C et al. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000; 47: 944–53.
88. Byne W, Buchsbaum MS, Mattiace LA et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 2002; 159: 59–65.
89. Cullen TJ, Walker MA, Parkinson N et al. A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr Res 2003; 60: 157–66.
90. Dorph-Petersen KA, Pierri JN, Sun Z et al. Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J Comp Neurol 2004; 472: 449–62.
91. Danos P, Schmidt A, Baumann B et al. Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study. Psychiatry Res 2005; 140: 281–9.
92. Danos P, Baumann B, Bernstein HG et al. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res 1998; 82: 1–10.
93. Byne W, Kidkardnee S, Tatusov A et al. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 2006; 85: 245–53.
94. Byne W, Fernandes J, Haroutunian V et al. Reduction of right medial pulvinar volume and neuron number in schizophrenia. Schizophr Res 2007; 90: 71–5.
95. Danos P, Baumann B, Kramer A et al. Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr Res 2003; 60: 141–55.
96. Danos P, Baumann B, Bernstein HG et al. The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study. Psychiatry Res 2002; 114: 1–9.
97. Young KA, Holcomb LA, Yazdani U et al. Elevated neuron number in the limbic thalamus in major depression. Am J Psychiatry 2004; 161: 1270–7.
98. Snyder PJ, Bogerts B, Wu H et al. Absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: an MRI and postmortem histologic study. J Neuroimaging 1998; 8: 159–63.
99. Andreasen NC. The role of the thalamus in schizophrenia. Can J Psychiatry 1997; 42: 27–33.
100. Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res 2005; 78: 87–93.
101. Watis L, Chen SH, Chua HC et al. Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review. J Neural Transm 2008; 115: 493–511.
102. Clinton SM, Ibrahim HM, Frey KA et al. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry 2005; 162: 1859–71.
103. Dixon G, Harper CG. No evidence for selective GABAergic interneuron deficits in the anterior thalamic complex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1045–51.
104. Roberts RC. Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. Schizophr Bull 2007; 33: 11–15.
105. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007; 9: 329–36.
106. Bogerts B, Falkai P, Haupts M et al. Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection. Schizophr Res 1990; 3: 295–301.
107. Lauer M, Beckmann H. The human striatum in schizophrenia. I. Increase in overall relative striatal volume in schizophrenics. Psychiatry Res 1997; 68: 87–98.
108. Lang DJ, Kopala LC, Vandorpe RA et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 2001; 158: 625–31.
109. Anderson SM, Bari AA, Pierce RC. Administration of the D1-like dopamine receptor antagonist SCH-23390 into the medial nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug-seeking behavior in rats. Psychopharmacology (Berl) 2003; 168: 132–8.
110. Lauer M, Johannes S, Fritzen S et al. Morphological abnormalities in nitric-oxide-synthase­-positive striatal interneurons of schizophrenic patients. Neuropsychobiology 2005; 52: 111–7.
111. Holt DJ, Bachus SE, Hyde TM et al. Reduced density of cholinergic interneurons in the ventral striatum in schizophrenia: an in situ hybridization study. Biol Psychiatry 2005; 58: 408–16.
112. Brown JS Jr. Effects of Bisphenol-A and Other Endocrine Disruptors Compared With Abnormalities of Schizophrenia: An Endocrine-Disruption Theory of Schizophrenia. Schizophr Bull 2008; 35(1): 256–78.
113. Goldstein JM, Seidman LJ, Makris N et al. Hypothalamic abnormalities in schizophrenia: sex effects and genetic vulnerability. Biol Psychiatry 2007; 61: 935–45.
114. Koolschijn PC, van Haren NE, Hulshoff Pol HE et al. Hypothalamus volume in twin pairs discordant for schizophrenia. Eur Neuropsychopharmacol 2008; 18: 312–5.
115. Mai JK, Berger K, Sofroniew MW. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced interindividual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 1993; 34: 133–54.
116. Bernstein HG, Stanarius A, Baumann B et al. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998; 83: 867–75.
117. Bernstein HG, Lendeckel U, Dobrowolny H et al. Beacon-like/ubiquitin-5-like immuno­reactivity is highly expressed in human hypothalamus and increased in haloperidol-treated schizophrenics and a rat model of schizophrenia. Psychoneuroendocrinology 2008; 33: 340–51.
118. Malidelis YI, Panayotacopoulou MT, van Heerikhuize JJ et al. Absence of a difference in the neurosecretory activity of supraoptic nucleus vasopressin neurons of neuroleptic-treated schizophrenic patients. Neuroendocrinology 2005; 82: 63–9.
119. Weinberger DR, Kleinman JE, Luchins DJ et al. Cerebellar pathology in schizophrenia: a controlled postmortem study. Am J Psychiatry 1980; 137: 359–61.
120. Luchins DJ, Morihisa JM, Weinberger DR et al. Cerebral asymmetry and cerebellar atrophy in schizophrenia: a controlled postmortem study. Am J Psychiatry 1981; 138: 1501–3.
121. Martin P, Albers M. Cerebellum and schizophrenia: a selective review. Schizophr Bull 1995; 21: 241–50.
122. Supprian T, Ulmar G, Bauer M et al. Cerebellar vermis area in schizophrenic patients – a post-mortem study. Schizophr Res 2000; 42: 19–28.
123. Tran KD, Smutzer GS, Doty RL et al. Reduced Purkinje cell size in the cerebellar vermis of elderly patients with schizophrenia. Am J Psychiatry 1998; 155: 1288–90.
124. Fatemi SH, Laurence JA, Araghi-Niknam M et al. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophr Res 2004; 69: 317–23.
125. Guidotti A, Auta J, Davis JM et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061–9.
126. Bernstein HG, Krell D, Braunewell KH et al. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. J Neurocytol 2001; 30: 661–70.
127. Karson CN, Griffin WS, Mrak RE et al. Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 1996; 27: 275–84.
128. Kyosseva SV, Elbein AD, Hutton TL et al. Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. Arch Gen Psychiatry 2000; 57: 685–91.
129. Falkai P, Honer WG, David S et al. No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study. Neuropathol Appl Neurobiol 1999; 25: 48–53.
130. Falkai P, Schneider T, Greve B et al. Reduced frontal and occipital lobe asymmetry on the CT-scans of schizophrenic patients. Its specificity and clinical significance. J Neural Transm 1995; 99: 63–77.
131. Vogeley K, Schneider-Axmann T, Pfeiffer U et al. Disturbed gyrification of the prefrontal region in male schizophrenic patients: A morphometric postmortem study. Am J Psychiatry 2000; 157: 34–9.
132. de Haan L, Bakker JM, de Haan P et al. Overview of neuropathological theories of schizophrenia: from degeneration to progressive developmental disorder. Effect of ischemic pretreatment on heat shock protein 72, neurologic outcome, and histopathologic outcome in a rabbit model of spinal cord ischemia. Psychopathology 2004; 37: 1–7.
133. Gorwood P, Pouchot J, Vinceneux P et al. Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level. Schizophr Res 2004; 66: 21–9.
134. Wagner-Jauregg J. Über die Einwirkung fieberhafter Erkrankungen auf Psychosen. Allgemeine Zeitschrift für Psychiatrie 1887; 27: 93–131.
135. Nunes SO, Borelli SD, Matsuo T et al. The association of the HLA in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 2005; 76: 195–8.
136. Torrey EF, Bartko JJ, Lun ZR et al. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007; 33: 729–36.
137. Schwarcz R, Hunter CA. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid? Schizophr Bull 2007; 33: 652–3.
138. Babulas V, Factor-Litvak P, Goetz R et al. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am J Psychiatry 2006; 163: 927–9.
139. Brown AS. The risk for schizophrenia from childhood and adult infections. Am J Psychiatry 2008; 165: 7–10.
140. Nyffeler M, Meyer U, Yee BK et al. Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience 2006; 143: 51–62.
141. Kamp HV. Nuclear changes in the white blood cells of patients with schizophrenic reaction: a preliminary report. J Neuropsychiatry 1962; 4: 1–3.
142. Hirata-Hibi M, Higashi S, Tachibana T et al. Stimulated lymphocytes in schizophrenia. Arch Gen Psychiatry 1982; 39: 82–7.
143. Kokai M, Morita Y, Fukuda H et al. Immunophenotypic studies on atypical lymphocytes in psychiatric patients. Psychiatry Res 1998; 77: 105–12.
144. DeLisi LE, Goodman S, Neckers LM et al. An analysis of lymphocyte subpopulations in schizophrenic patients. Biol Psychiatry 1982; 17: 1003–9.
145. Fieve RR, Blumenthal B, Little B. The relationship of atypical lymphocytes, phenothiazines, and schizophrenia. Arch Gen Psychiatry 1966; 15: 529–34.
146. Rudolf S, Schlenke P, Broocks A et al. Search for atypical lymphocytes in schizophrenia. World J Biol Psychiatry 2004; 5: 33–7.
147. Watanabe Y, Nakayama T, Nagakubo D et al. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol 2006; 176: 848–56.
148. Levite M, Chowers Y, Ganor Y et al. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. Eur J Immunol 2001; 31: 3504–12.
149. Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 2007; 41: 3–7.
150. Craddock RM, Lockstone HE, Rider DA et al. Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS ONE 2007; 2: e692.
151. Schuld A, Hinze-Selch D, Pollmaecher T. Cytokine network in patients with schizophrenia and its significance for the pathophysiology of the illness. Nervenarzt 2004; 75: 215–26.
152. Borda T, Perez Rivera R, Joensen L et al. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 2002; 168: 3667–74.
153. Tanaka S, Matsunaga H, Kimura M et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003; 14: 155–64.
154. Elenkov IJ, Wilder RL, Chrousos GP et al. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595–638.
155. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006; 10: 131–48.
156. Akhondzadeh S, Tabatabaee M, Amini H et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179–85.
157. Potvin S, Stip E, Sepehry AA et al. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biol Psychiatry 2007, [doi: 10. 1016/j.biopsych.2007. 1009.1024].
158. Shirts BH, Wood J, Yolken RH et al. Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta. Schizophr Res 2006; 88: 235–44.
159. Papiol S, Molina V, Desco M et al. Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. Neuroimage 2005; 27: 1002–6.
160. Schwarz MJ, Kronig H, Riedel M et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256: 72–6.
161. Lencz T, Morgan TV, Athanasiou M et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007; 12: 572–80.
162. Bayer TA, Buslei R, Havas L, et al. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999, 271, 126–128
163. Radewicz K, Garey LJ, Gentleman SM, et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000, 59, 137–150
164. Arnold SE, Trojanowski JQ, Gur RE, et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998, 55, 225–232
165. Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res 2000, 93, 103–110
166. Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm 1997, 104, 1361–1370
167. Steiner J, Mawrin C, Ziegeler A, et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006, 112, 305–316
168. Togo T, Akiyama H, Kondo H, et al. Expression of CD40 in the brain of Alzheimer′s disease and other neurological diseases. Brain Res 2000, 885, 117–121
169. Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42, 151–157
170. Arnold SE, Trojanowski JQ, Gur RE et al. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998; 55: 225–32.
171. Falke E, Han LY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res 2000; 93: 103–10.
172. Kurumaji A, Wakai T, Toru M. Decreases in peripheral-type benzodiazepine receptors in postmortem brains of chronic schizophrenics. J Neural Transm 1997; 104: 1361–70.
173. Steiner J, Mawrin C, Ziegeler A et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006; 112: 305–16.
174. Togo T, Akiyama H, Kondo H et al. Expression of CD40 in the brain of Alzheimer′s disease and other neurological diseases. Brain Res 2000; 885: 117–21.
175. Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151–7.